Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
43.99
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Bristol Myers Squibb Stock a Buy Now?
January 25, 2024
This healthcare stock has seen healthier days.
Via
The Motley Fool
Uncovering Dividend Opportunities with NYSE:BMY.
January 25, 2024
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential.
Via
Chartmill
Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends
January 16, 2024
Via
Benzinga
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
January 26, 2024
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.
Via
InvestorPlace
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.
Via
Benzinga
Exposures
Product Safety
7 Beaten-Down Value Stocks Poised for an Epic Turnaround
January 23, 2024
Battered value stocks could be priced for an epic rebound in 2024 and beyond. These seven can quickly escape Wall Street's penalty box.
Via
InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Via
Benzinga
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
January 23, 2024
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight...
Via
Benzinga
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
January 11, 2024
Via
Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
January 05, 2024
Via
Benzinga
Why NYSE:BMY qualifies as a good dividend investing stock.
January 04, 2024
Balancing Dividends and Fundamentals: The Case of BRISTOL-MYERS SQUIBB CO (NYSE:BMY).
Via
Chartmill
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer
January 22, 2024
Bristol Myers' Opdivo + Yervoy combo shows 79% reduced risk in MSI-H/dMMR metastatic colorectal cancer.
Via
Benzinga
Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes
January 19, 2024
Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on...
Via
Benzinga
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
January 18, 2024
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?
Via
Benzinga
Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits
January 16, 2024
In 2024, the Inflation Reduction Act limits out-of-pocket drug costs to $3,300 annually, with further reductions to $2,000 in 2025.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...
Via
Benzinga
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Bullish Continuation In '24? 3 Market Areas To Watch
January 10, 2024
This article discusses 3 market areas that should outperform dramatically over the next 12 months...
Via
Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
January 06, 2024
There's more than meets the eye with all three of these dividend stocks.
Via
The Motley Fool
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
3 Dividend Stocks for Strong Returns in 2024 and Beyond
January 04, 2024
Investors should consider these three dividend stocks for 2024 and beyond, as they offer compelling yields and safety.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
7 Stocks Primed for a Spectacular Comeback in 2024
January 03, 2024
Although the usual suspects may carry confidence, these underappreciated comeback stocks might deliver the goods in 2024.
Via
InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...
Via
Benzinga
3 Strong Dividend Stocks to Buy Early On in 2024
January 03, 2024
The markets are always looking forward, and you should, too. Here are three dividend stocks to buy now.
Via
The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 29, 2023
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.